United States: The DTC-Telehealth Epicenter
Direct-to-consumer telehealth, 'optimization' culture, and marketing-driven medicalization
Evidence grade 5 of 5, Settled. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- FDA-approved drugs delivered through a permissive DTC-advertising and cash-pay telehealth model
Reference only. Not medical advice.
What can go wrong
Marketing-driven medicalization risks overtreatment: men prescribed testosterone without confirmed hypogonadism face polycythemia, cardiovascular questions, and, critically, infertility from HPG-axis suppression, often poorly disclosed in DTC funnels. Cash-pay telehealth can under-emphasize cardiovascular screening and nitrate contraindications for PDE5 drugs. Compounded products and influencer-promoted 'protocols' add quality and off-label concerns.
This is something to take to a clinician. The Atlas can tell you what is known about united states: the dtc-telehealth epicenter in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
The United States is the epicenter of direct-to-consumer (DTC) men's sexual medicine and the reference point against which other regions are measured. It is one of only two countries (with New Zealand) that permits DTC prescription-drug advertising, which, combined with cash-pay telehealth platforms (Hims, Ro/Roman, BlueChew, Hone Health, Maximus and others), built a subscription economy around PDE5 inhibitors and testosterone. The defining feature is 'optimization' culture: framing testosterone and sexual performance as upgradeable metrics rather than treating diagnosed disease. The mid-2010s 'low-T' marketing wave drove a documented surge in testosterone prescribing, much of it to men without rigorous hypogonadism diagnosis, a textbook case of marketing-driven medicalization.
The country that turned erections and testosterone into a direct-to-consumer subscription business.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
Pharmacology is standard FDA-approved drug action; the U.S. distinctive is the demand-and-delivery engine. DTC advertising legality plus telehealth's asynchronous prescribing lowered friction so far that the bottleneck shifted from diagnosis to marketing. 'Optimization' reframes population-normal testosterone and age-related change as deficits to be corrected, expanding the treated population well beyond classical hypogonadism.
Safety in detail
Testosterone therapy and related interventions involve significant physiological effects and require evaluation and monitoring by a qualified physician. Subscription and self-optimization channels can under-deliver the screening and monitoring that safe use requires.
Replacement is not the same as a cycle
Even within 'optimization' culture, the line between physiological replacement and pushing toward high-normal/supraphysiological targets is frequently blurred; the latter raises erythrocytosis, cardiovascular, and fertility risks without added proven benefit.
What it does to fertility
Exogenous testosterone suppresses spermatogenesis and can cause infertility, a major concern when 'optimization' marketing reaches younger men; fertility-sparing alternatives (e.g., enclomiphene, hCG) are themselves heavily marketed.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- Confirmed-low testosterone before TRT
- Hematocrit/hemoglobin
- PSA where indicated
- Cardiovascular risk assessment
- Fertility counseling
What people get wrong
Often saidEasier access through telehealth means better men's-health care
ActuallyLower friction can help genuine patients but also enables overtreatment and under-screening; access is not the same as appropriate diagnosis.
Often saidOptimizing testosterone to high-normal makes healthy men better
ActuallyThere is no good evidence that pushing testosterone above replacement in non-hypogonadal men improves outcomes; it adds risk, including infertility.
Who profits, and who pushes back
Telehealth/optimization brands (Hims, Roman, Hone, Maximus)
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Commercial sellers; their marketing claims are promotional, not independent clinical endorsement.
Endocrine Society
Recommends diagnosing hypogonadism only with symptoms plus repeated low morning testosterone, and warns against treating age-related decline or low-T marketing as disease.
FDA
Issued 2015 labeling action stating testosterone is not approved for low levels due to aging alone and flagging possible cardiovascular signals, pushing back on broad 'low-T' prescribing.
Adriane Fugh-Berman
Documents how disease-awareness marketing and DTC advertising manufacture demand and medicalize normal aging, a frequently cited critique of the low-T campaigns.
How we got here
The U.S. liberalized DTC prescription-drug advertising via FDA guidance in 1997, unleashing direct consumer demand generation. Viagra's 1998 launch became a cultural phenomenon. The 2012-2014 'low-T' campaigns (e.g., AndroGel marketing) drove a sharp rise in testosterone prescriptions, prompting FDA scrutiny and a 2015 labeling caution that benefits for age-related low testosterone were unproven. From ~2017 onward, telehealth startups (Hims 2017, Roman 2017) built the subscription model; Hone Health, Maximus, and influencer-driven 'optimization' brands followed.
- 1997FDA guidance liberalizes DTC prescription-drug advertising
- 1998Viagra launches; cultural phenomenon
- 2012-2014'Low-T' marketing surge expands TRT prescribing
- 2015FDA cautions that TRT benefit for age-related low-T is unproven
- 2017+Hims and Roman launch the DTC telehealth subscription model
- 2020s'Optimization' brands (Hone, Maximus) and influencers scale
Set against the alternatives
Compared with most of the world, the U.S. is an outlier on the demand side rather than the drug side: the molecules (sildenafil, tadalafil, testosterone esters) are the same globally, but legal DTC advertising plus cash-pay asynchronous telehealth strips out the diagnostic friction that gatekeeps these therapies elsewhere. Where European and most Asian systems route men through in-person evaluation and (often) public payers, the U.S. cash-pay subscription model reframes therapy as a consumer 'optimization' purchase. The trade-off is access and convenience versus weaker diagnostic rigor and a documented tendency to treat population-normal hormone levels.
| Platform | Core focus | Visit model | Distinctive |
|---|---|---|---|
| Hims/Hers | Multi-category (ED, hair, mental) | Mostly asynchronous | Broad subscription brand |
| Ro (Roman) | ED, TRT support, fertility | Async + some live | Enclomiphene, fertility-aware |
| BlueChew | ED only | Async, chewable PDE5 | Single-condition specialist |
| Hone Health | Testosterone/TRT | Live physician visits | Direct TRT, lab-driven |
| Maximus | Optimization/hormones | Higher-touch protocols | Enclomiphene, 'biohacker' framing |
What we do not know
- How much DTC TRT prescribing falls outside guideline-defined hypogonadism?
- Will FDA tighten oversight of compounded and influencer-marketed hormone products?
- Does frictionless telehealth improve or degrade screening quality?
What could change
Compounded GLP-1 + sexual-health bundlesDTC platforms cross-selling metabolic, hair, and sexual-health subscriptions in one cart.Regulatory scrutiny of async prescribingState boards and the FTC examining telehealth advertising, refill autopilot, and minimal-evaluation prescribing.Enclomiphene and SERM-based 'TRT alternatives'Fertility-preserving testosterone-raising approaches marketed against classic exogenous TRT.Outcomes and safety data on cash-pay TRTPressure for real-world monitoring evidence as subscription hormone use scales.
Legal status
Access is frictionless and cash-pay: telehealth intake, asynchronous prescribing, and home delivery, supported by legal DTC advertising and influencer funnels. Traditional clinic and insurance pathways coexist but the DTC channel sets the cultural tone.
Status current as of July 2026. Regulatory positions change, sometimes quickly.
At a glance
- DTC advertising
- U.S. and New Zealand are the only countries permitting DTC prescription-drug ads
- Telehealth platforms
- Hims, Ro/Roman, BlueChew, Hone Health, Maximus, etc.
- 'Low-T' era
- Mid-2010s marketing surge expanded TRT prescribing
- Model
- Cash-pay subscription; compounded and generic products
- Cultural frame
- 'Optimization'/biohacking rather than disease treatment
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about United States: The DTC-Telehealth Epicenter. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
No sources recorded for this entry yet. Nothing on this page can be checked against a citation until that changes, so treat it as a summary awaiting its evidence.